

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/521,410  
Applicant : ULLRICH et al  
Filed : January 18, 2005  
TC/A.U. : 1642  
Examiner : Peter J. Reddig

Docket No. : 2923-679  
Customer No. : 6449  
Confirmation No.: 7025

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Restriction Requirement dated June 1, 2007, the response term having been extended by one month by paper filed of even date herewith, the applicants hereby elect Group 2. Within Group 2, if the Examiner's requirement is correctly understood, the applicants hereby elect the inhibition of AXL protein. This election is with traverse, especially with respect to Groups 2-4, since there is a shared linking technical concept, namely the inhibition of the AXL gene function by using suitable inhibitors. This application is a U.S. National Phase Entry application from a PCT International Application, so that the PCT Rules of unity of invention apply, and the special technical feature, namely the inhibition of the AXL gene function, is not taught by the reference relied upon by the Examiner. Accordingly, withdrawal of the Restriction Requirement, at least with respect to Groups 2-4, is believed in order and is awaited.

The Examiner required a species election for Group 2, and in response to this requirement the applicants elect species 5, namely an antibody directed to the AXL protein.

Early and favorable action on the merits is awaited.

Respectfully submitted,

/Robert B. Murray/

By

Robert B. Murray  
Attorney for Applicant  
Registration No. 22,980  
ROTHWELL, FIGG, ERNST & MANBECK  
1425 K. Street, Suite 800  
Washington, D.C. 20005  
Telephone: (202) 783-6040

RBM/cb